TransCode Therapeutics
RNAZ
4 hedge funds and large institutions have $282K invested in TransCode Therapeutics in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, reducing their positions, and closing their positions.
300% more funds holding
Funds holding: 1 → 4 (+3)
0% less ownership
Funds ownership: 0% → 0% (-0%)
41% less capital invested
Capital invested by funds: $477K → $282K (-$195K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$251K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$126K |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
+$126K |
| 4 |
VF
Virtu Financial
New York
|
+$62.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$31.4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $126K | +$126K | +2 | +40% |
|
|
2
UBS Group
Zurich,
Switzerland
| $73.7K | +$251K | +4 | New |
|
|
TCM
3
Tang Capital Management
San Diego,
California
| $42.2K | +$126K | +2 | New |
|
|
VF
4
Virtu Financial
New York
| $16K | +$62.8K | +1 | New |
|
5
Two Sigma Investments
New York
| $8.12K | – | – | – |
|
|
HF
6
HRT Financial
New York
| $8K | – | – | – |
|
|
WAM
7
Warberg Asset Management
Winnetka,
Illinois
| $5.03K | – | – | – |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| $2.69K | – | – | – |
|
9
Wells Fargo
San Francisco,
California
| $6 | – | – | – |
|
|
FPFS
10
First Personal Financial Services
Charlotte,
North Carolina
| $1 | – | – | – |
|
|
11
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$31.4K | – | – |
|
RNAZ Hedge Fund Activity: Q3 2023 in Review
4 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in TransCode Therapeutics (RNAZ) for Q3 2023, worth a combined $282K — down 41% from $477K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new RNAZ positions and 0 closed out — a net gain of 3 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $251K. The largest seller was Susquehanna International Group, cutting an estimated $31.4K.
- 4 institutional investors held TransCode Therapeutics (RNAZ) as of Q3 2023, up from 1 in Q2 2023.
- Funds reported $282K of TransCode Therapeutics stock for Q3 2023, down 41% quarter-over-quarter.
- 3 funds opened new TransCode Therapeutics positions in Q3 2023 and 0 closed out, a net change of +3 holders.
- The largest TransCode Therapeutics buyer in Q3 2023 was UBS Group, an estimated $251K added.
- The largest TransCode Therapeutics seller in Q3 2023 was Susquehanna International Group, an estimated $31.4K sold.
Based on aggregated 13F filings for Q3 2023.